{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:53:24Z","timestamp":1790812404412,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2022-NR067509"],"award-info":[{"award-number":["RS-2022-NR067509"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021M3E5E3080847"],"award-info":[{"award-number":["2021M3E5E3080847"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03813-y","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T22:18:03Z","timestamp":1748297883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Construction and validation of a cell based reporter assay for identifying inhibitors of SARS coronavirus 2 RNA dependent RNA polymerase activity"],"prefix":"10.1038","volume":"15","author":[{"given":"Eunjeong","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haelim","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JinAh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungtaek","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inseong","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Bong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Gwin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"3813_CR1","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijid.2020.03.004","volume":"94","author":"D Wu","year":"2020","unstructured":"Wu, D., Wu, T., Liu, Q. & Yang, Z. The SARS-CoV-2 outbreak: what we know. Int. J. Infect. Dis. 94, 44\u201348 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"3813_CR2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.14202\/vetworld.2021.190-199","volume":"14","author":"KA Al-Salihi","year":"2021","unstructured":"Al-Salihi, K. A. & Khalaf, J. M. The emerging SARS-CoV, MERS-CoV, and SARS-CoV-2: an insight into the viruses zoonotic aspects. Vet. World. 14, 190\u2013199 (2021).","journal-title":"Vet. World"},{"key":"3813_CR3","doi-asserted-by":"publisher","first-page":"106054","DOI":"10.1016\/j.ijantimicag.2020.106054","volume":"56","author":"A Sharma","year":"2020","unstructured":"Sharma, A., Tiwari, S., Deb, M. K. & Marty, J. L. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int. J. Antimicrob. Agents. 56, 106054 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"3813_CR4","doi-asserted-by":"publisher","first-page":"117793222110258","DOI":"10.1177\/11779322211025876","volume":"15","author":"R Gorkhali","year":"2021","unstructured":"Gorkhali, R. et al. Structure and function of major SARS-CoV-2 and SARS-CoV proteins. Bioinform Biol. Insights. 15,\u00a011779322211025876 (2021).","journal-title":"Bioinform Biol. Insights"},{"key":"3813_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","volume":"19","author":"H Yang","year":"2021","unstructured":"Yang, H. & Rao, Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol. 19, 685\u2013700 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"3813_CR6","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.3390\/microorganisms9122481","volume":"9","author":"R Razali","year":"2021","unstructured":"Razali, R., Asis, H. & Budiman, C. Structure-Function characteristics of SARS-CoV-2 proteases and their potential inhibitors from microbial sources. Microorganisms 9, 2481 (2021).","journal-title":"Microorganisms"},{"key":"3813_CR7","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3390\/cells10040821","volume":"10","author":"R Yadav","year":"2021","unstructured":"Yadav, R. et al. Role of structural and Non-Structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells 10, 821 (2021).","journal-title":"Cells"},{"key":"3813_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2217\/fvl-2021-0335","volume":"18","author":"J Wu","year":"2023","unstructured":"Wu, J. et al. SARS-CoV-2 RNA-dependent RNA polymerase as a target for high-throughput drug screening. Future Virol. 18, 51\u201362 (2023).","journal-title":"Future Virol."},{"key":"3813_CR9","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1038\/s41467-019-10280-3","volume":"10","author":"RN Kirchdoerfer","year":"2019","unstructured":"Kirchdoerfer, R. N. & Ward, A. B. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat. Commun. 10, 2342 (2019).","journal-title":"Nat. Commun."},{"key":"3813_CR10","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/j.cell.2020.07.033","volume":"182","author":"J Chen","year":"2020","unstructured":"Chen, J. et al. Structural basis for Helicase-Polymerase coupling in the SARS-CoV-2 Replication-Transcription complex. Cell. 182, 1560\u20131573 (2020).","journal-title":"Cell"},{"key":"3813_CR11","doi-asserted-by":"publisher","first-page":"8822","DOI":"10.1093\/nar\/gkab677","volume":"49","author":"B Wang","year":"2021","unstructured":"Wang, B., Svetlov, D. & Artsimovitch, I. NMPylation and de-NMPylation of SARS-CoV-2 nsp9 by the NiRAN domain. Nucleic Acids Res. 49, 8822 (2021).","journal-title":"Nucleic Acids Res."},{"key":"3813_CR12","doi-asserted-by":"publisher","first-page":"e04502","DOI":"10.1016\/j.heliyon.2020.e04502","volume":"6","author":"J Ahmad","year":"2020","unstructured":"Ahmad, J., Ikram, S., Ahmad, F., Rehman, I. U. & Mushtaq, M. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) \u2013 A drug repurposing study. Heliyon 6, e04502 (2020).","journal-title":"Heliyon"},{"key":"3813_CR13","doi-asserted-by":"publisher","first-page":"5853","DOI":"10.1021\/acs.jcim.0c00501","volume":"60","author":"R Wang","year":"2020","unstructured":"Wang, R., Hozumi, Y., Yin, C. & Wei, G. W. Decoding SARS-CoV-2 transmission and evolution and ramifications for COVID-19 diagnosis, vaccine, and medicine. J. Chem. Inf. Model. 60, 5853\u20135865 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"3813_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41580-021-00432-z","volume":"23","author":"B Malone","year":"2022","unstructured":"Malone, B., Urakova, N., Snijder, E. J. & Campbell, E. A. Structures and functions of coronavirus replication\u2013transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell. Biol. 23, 21\u201339 (2022).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"3813_CR15","doi-asserted-by":"publisher","first-page":"107774","DOI":"10.1016\/j.celrep.2020.107774","volume":"31","author":"Q Peng","year":"2020","unstructured":"Peng, Q. et al. Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2. Cell Rep. 31, 107774 (2020).","journal-title":"Cell Rep."},{"key":"3813_CR16","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1016\/j.cellin.2022.100046","volume":"1","author":"T Uppal","year":"2022","unstructured":"Uppal, T. et al. Screening of SARS-CoV-2 antivirals through a cell-based RNA-dependent RNA polymerase (RdRp) reporter assay. Cell Insight. 1, 100046 (2022).","journal-title":"Cell Insight"},{"key":"3813_CR17","doi-asserted-by":"publisher","first-page":"855496","DOI":"10.3389\/fimmu.2022.855496","volume":"13","author":"L Tian","year":"2022","unstructured":"Tian, L. et al. Molnupiravir and its antiviral activity against COVID-19. Front. Immunol. 13, 855496 (2022).","journal-title":"Front. Immunol."},{"key":"3813_CR18","doi-asserted-by":"publisher","first-page":"113058","DOI":"10.1016\/j.biopha.2022.113058","volume":"150","author":"HR Jonsdottir","year":"2022","unstructured":"Jonsdottir, H. R. et al. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro. Biomed. Pharmacother. 150, 113058 (2022).","journal-title":"Biomed. Pharmacother"},{"key":"3813_CR19","doi-asserted-by":"publisher","first-page":"e06435","DOI":"10.1016\/j.heliyon.2021.e06435","volume":"7","author":"MK Hasan","year":"2021","unstructured":"Hasan, M. K. et al. Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation. Heliyon 7, e06435 (2021).","journal-title":"Heliyon"},{"key":"3813_CR20","doi-asserted-by":"crossref","unstructured":"Xue, Y. et al. Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV\u20102. MedComm. 4, e254 (2023).","DOI":"10.1002\/mco2.254"},{"key":"3813_CR21","doi-asserted-by":"publisher","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","volume":"253","author":"AA Elfiky","year":"2020","unstructured":"Elfiky, A. A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular Docking study. Life Sci. 253, 117592 (2020).","journal-title":"Life Sci."},{"key":"3813_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s42003-022-03101-9","volume":"5","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. Commun. Biol. 5, 154 (2022).","journal-title":"Commun. Biol."},{"key":"3813_CR23","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/v14071369","volume":"14","author":"CW Chang","year":"2022","unstructured":"Chang, C. W. et al. A newly engineered A549 cell line expressing ACE2 and TMPRSS2 is highly permissive to SARS-CoV-2, including the Delta and Omicron variants. Viruses 14, 1369 (2022).","journal-title":"Viruses"},{"key":"3813_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-pharmtox-121120-012309","volume":"62","author":"S Pandamooz","year":"2022","unstructured":"Pandamooz, S. et al. Experimental models of SARS-CoV-2 infection: possible platforms to study COVID-19 pathogenesis and potential treatments. Annu. Rev. Pharmacol. Toxicol. 62, 25\u201353 (2022).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"3813_CR25","doi-asserted-by":"publisher","first-page":"1205238","DOI":"10.3389\/fphar.2023.1205238","volume":"14","author":"E Burhan","year":"2023","unstructured":"Burhan, E. et al. Evaluation of safety and effectiveness of Remdesivir in treating COVID-19 patients after emergency use authorization study. Front. Pharmacol. 14, 1205238 (2023).","journal-title":"Front. Pharmacol."},{"key":"3813_CR26","doi-asserted-by":"publisher","first-page":"107786","DOI":"10.1016\/j.isci.2023.107786","volume":"26","author":"A Zibat","year":"2023","unstructured":"Zibat, A. et al. N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody. iScience 26, 107786 (2023).","journal-title":"iScience"},{"key":"3813_CR27","doi-asserted-by":"publisher","first-page":"115279","DOI":"10.1016\/j.bcp.2022.115279","volume":"205","author":"X Xu","year":"2022","unstructured":"Xu, X. et al. An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: promises and challenges. Biochem. Pharmacol. 205, 115279 (2022).","journal-title":"Biochem. Pharmacol."},{"key":"3813_CR28","doi-asserted-by":"publisher","first-page":"e1009384","DOI":"10.1371\/journal.pcbi.1009384","volume":"17","author":"A Dwivedy","year":"2021","unstructured":"Dwivedy, A. et al. Characterization of the NiRAN domain from RNA-dependent RNA polymerase provides insights into a potential therapeutic target against SARS-CoV-2. PLOS Comput. Biol. 17, e1009384 (2021).","journal-title":"PLOS Comput. Biol."},{"key":"3813_CR29","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11095-020-02851-7","volume":"37","author":"E Weisberg","year":"2020","unstructured":"Weisberg, E. et al. Repurposing of kinase inhibitors for treatment of COVID-19. Pharm. Res. 37, 167 (2020).","journal-title":"Pharm. Res."},{"key":"3813_CR30","doi-asserted-by":"publisher","first-page":"104591","DOI":"10.1016\/j.compbiomed.2021.104591","volume":"135","author":"SK Mondal","year":"2021","unstructured":"Mondal, S. K. et al. In Silico analysis of RNA-dependent RNA polymerase of the SARS-CoV-2 and therapeutic potential of existing antiviral drugs. Comput. Biol. Med. 135, 104591 (2021).","journal-title":"Comput. Biol. Med."},{"key":"3813_CR31","doi-asserted-by":"publisher","first-page":"103553","DOI":"10.1016\/j.isci.2021.103553","volume":"25","author":"E Geerling","year":"2022","unstructured":"Geerling, E. et al. Roles of antiviral sensing and type I interferon signaling in the restriction of SARS-CoV-2 replication. iScience 25, 103553 (2022).","journal-title":"iScience"},{"key":"3813_CR32","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.3390\/jcm9082399","volume":"9","author":"JS Min","year":"2020","unstructured":"Min, J. S., Kim, G. W., Kwon, S. & Jin, Y. H. A Cell-Based reporter assay for screening inhibitors of MERS coronavirus RNA-Dependent RNA polymerase activity. J. Clin. Med. 9, 2399 (2020).","journal-title":"J. Clin. Med."},{"key":"3813_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ab.2010.04.004","volume":"403","author":"JC Lee","year":"2010","unstructured":"Lee, J. C. et al. A cell-based reporter assay for inhibitor screening of hepatitis C virus RNA-dependent RNA polymerase. Anal. Biochem. 403, 52\u201362 (2010).","journal-title":"Anal. Biochem."},{"key":"3813_CR34","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","volume":"7","author":"W Yan","year":"2022","unstructured":"Yan, W., Zheng, Y., Zeng, X., He, B. & Cheng, W. Structural biology of SARS-CoV-2: open the door for novel therapies. Signal. Transduct. Target. Ther. 7, 26 (2022).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"3813_CR35","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3390\/biomedicines9080996","volume":"9","author":"JS Min","year":"2021","unstructured":"Min, J. S., Kwon, S. & Jin, Y. H. SARS-CoV-2 RdRp inhibitors selected from a Cell-Based SARS-CoV-2 RdRp activity assay system. Biomedicines 9, 996 (2021).","journal-title":"Biomedicines"},{"key":"3813_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbrc.2021.07.050","volume":"571","author":"F Begum","year":"2021","unstructured":"Begum, F., Srivastava, A. K. & Ray, U. Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): in silico-molecular insight. Biochem. Biophys. Res. Commun. 571, 26\u201331 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3813_CR37","doi-asserted-by":"publisher","first-page":"eabo0718","DOI":"10.1126\/scitranslmed.abo0718","volume":"14","author":"LJ Stevens","year":"2022","unstructured":"Stevens, L. J. et al. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to Remdesivir by distinct mechanisms. Sci. Transl Med. 14, eabo0718 (2022).","journal-title":"Sci. Transl Med."},{"key":"3813_CR38","first-page":"793","volume":"609","author":"GJ Park","year":"2022","unstructured":"Park, G. J. et al. The mechanism of RNA capping by SARS-CoV-2. Nature 609, 793\u2013800 (2022).","journal-title":"Nature"},{"key":"3813_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bbrc.2020.11.043","volume":"538","author":"MG Santoro","year":"2021","unstructured":"Santoro, M. G. & Carafoli, E. Remdesivir: From Ebola to COVID-19. Biochem. Biophys. Res. Commun. 538, 145\u2013150 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"3813_CR40","doi-asserted-by":"publisher","first-page":"107940","DOI":"10.1016\/j.celrep.2020.107940","volume":"32","author":"AJ Pruijssers","year":"2020","unstructured":"Pruijssers, A. J. et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell. Rep. 32, 107940 (2020).","journal-title":"Cell. Rep."},{"key":"3813_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-20542-0","volume":"12","author":"G Kokic","year":"2021","unstructured":"Kokic, G. et al. Mechanism of SARS-CoV-2 polymerase stalling by Remdesivir. Nat. Commun. 12, 1\u20137 (2021).","journal-title":"Nat. Commun."},{"key":"3813_CR42","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"RT Eastman","year":"2020","unstructured":"Eastman, R. T. et al. A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent. Sci. 6, 672\u2013683 (2020). Remdesivir.","journal-title":"ACS Cent. Sci."},{"key":"3813_CR43","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/cells10051052","volume":"10","author":"RH Pirzada","year":"2021","unstructured":"Pirzada, R. H., Haseeb, M., Batool, M., Kim, M. & Choi, S. Remdesivir and Ledipasvir among the FDA-Approved antiviral drugs have potential to inhibit SARS-CoV-2 replication. Cells 10, 1052 (2021).","journal-title":"Cells"},{"key":"3813_CR44","doi-asserted-by":"publisher","first-page":"102396","DOI":"10.1016\/j.dsx.2022.102396","volume":"16","author":"AK Singh","year":"2022","unstructured":"Singh, A. K., Singh, A., Singh, R. & Misra, A. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes Metab. Syndr. Clin. Res. Rev. 16, 102396 (2022).","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"3813_CR45","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","volume":"28","author":"F Kabinger","year":"2021","unstructured":"Kabinger, F. et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 28, 740\u2013746 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"3813_CR46","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1592\/phco.29.10.1212","volume":"29","author":"AM Jenh","year":"2009","unstructured":"Jenh, A. M., Thio, C. L. & Pham, P. A. Tenofovir for the treatment of hepatitis B virus. Pharmacother J. Hum. Pharmacol. Drug Ther. 29, 1212\u20131227 (2009).","journal-title":"Pharmacother J. Hum. Pharmacol. Drug Ther."},{"key":"3813_CR47","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/cld.332","volume":"3","author":"MV Lin","year":"2014","unstructured":"Lin, M. V. & Chung, R. Recent FDA approval of Sofosbuvir and Simeprevir. Implications for current HCV treatment. Clin. Liver Dis. 3, 65\u201368 (2014).","journal-title":"Clin. Liver Dis."},{"key":"3813_CR48","doi-asserted-by":"publisher","first-page":"105078","DOI":"10.1016\/j.antiviral.2021.105078","volume":"190","author":"J Zhao","year":"2021","unstructured":"Zhao, J. et al. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. Antiviral Res. 190, 105078 (2021).","journal-title":"Antiviral Res."},{"key":"3813_CR49","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/17425255.2022.2112175","volume":"18","author":"M Yang","year":"2022","unstructured":"Yang, M. & Xu, X. Important roles of transporters in the pharmacokinetics of anti-viral nucleoside\/nucleotide analogs. Expert Opin. Drug Metab. Toxicol. 18, 483 (2022).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"3813_CR50","doi-asserted-by":"publisher","first-page":"6851","DOI":"10.3390\/cimb45080433","volume":"45","author":"PN Kamzeeva","year":"2023","unstructured":"Kamzeeva, P. N., Aralov, A. V., Alferova, V. A. & Korshun, V. A. Recent advances in molecular mechanisms of nucleoside antivirals. Curr. Issues Mol. Biol. 45, 6851\u20136879 (2023).","journal-title":"Curr. Issues Mol. Biol."},{"key":"3813_CR51","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.bcp.2004.06.012","volume":"68","author":"S Gallois-Montbrun","year":"2004","unstructured":"Gallois-Montbrun, S. et al. Broad specificity of human phosphoglycerate kinase for antiviral nucleoside analogs. Biochem. Pharmacol. 68, 1749\u20131756 (2004).","journal-title":"Biochem. Pharmacol."},{"key":"3813_CR52","doi-asserted-by":"publisher","first-page":"350","DOI":"10.25122\/jml-2021-0175","volume":"15","author":"MAS Elgohary","year":"2022","unstructured":"Elgohary, M. A. S. et al. Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial. J. Med. Life. 15, 350 (2022).","journal-title":"J. Med. Life"},{"key":"3813_CR53","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s40265-023-01926-0","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair, H. A. Remdesivir: A review in COVID-19. Drugs 83, 1215\u20131237 (2023).","journal-title":"Drugs"},{"key":"3813_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2023.1253799","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang, Y. et al. Adverse events associated with Molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system. Front. Pharmacol. 14, 1\u201311 (2023).","journal-title":"Front. Pharmacol."},{"key":"3813_CR55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmi.2022.07.006","volume":"29","author":"R Polo","year":"2023","unstructured":"Polo, R. et al. Daily Tenofovir disoproxil fumarate\/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers. Clin. Microbiol. Infect. 29, 85\u201393 (2023).","journal-title":"Clin. Microbiol. Infect."},{"key":"3813_CR56","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1021\/acs.jmedchem.1c00335","volume":"65","author":"T Pillaiyar","year":"2022","unstructured":"Pillaiyar, T. & Laufer, S. Kinases as potential therapeutic targets for Anti-coronaviral therapy. J. Med. Chem. 65, 955\u2013982 (2022).","journal-title":"J. Med. Chem."},{"key":"3813_CR57","doi-asserted-by":"crossref","unstructured":"Boytz, R. M. et al. Anti-SARS-CoV-2 activity of targeted kinase inhibitors: repurposing clinically available drugs for COVID-19 therapy. J Med. Virol. 95, e28157 (2023).","DOI":"10.1002\/jmv.28157"},{"issue":"13","key":"3813_CR58","first-page":"7","volume":"131","author":"A Shannon","year":"2022","unstructured":"Shannon, A. et al. A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase. Nat. Commun 131(13), 7\u20139 (2022).","journal-title":"Nat. Commun"},{"key":"3813_CR59","doi-asserted-by":"crossref","unstructured":"Gandek, T. B., van der Koog, L. & Nagelkerke, A. A. Comparison of cellular uptake mechanisms, delivery efficacy, and intracellular fate between liposomes and extracellular vesicles. Adv Healthc. Mater. 12, e2300319 (2023).","DOI":"10.1002\/adhm.202300319"},{"key":"3813_CR60","doi-asserted-by":"publisher","first-page":"737288","DOI":"10.3389\/fmicb.2021.737288","volume":"12","author":"K Nishino","year":"2021","unstructured":"Nishino, K., Yamasaki, S., Nakashima, R., Zwama, M. & Hayashi-Nishino, M. Function and inhibitory mechanisms of multidrug efflux pumps. Front. Microbiol. 12, 737288 (2021).","journal-title":"Front. Microbiol."},{"key":"3813_CR61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025866118","volume":"118","author":"X He","year":"2021","unstructured":"He, X. et al.\u00a0Generation of SARS-CoV-2 reporter replicon for high- throughput antiviral screening and testing.\u00a0Proc. Natl. Acad. Sci. U.S.A 118,\u00a0e2025866118 (2021)","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"3813_CR62","doi-asserted-by":"publisher","DOI":"10.5772\/INTECHOPEN.114041","author":"HA Ahmad","year":"2024","unstructured":"Ahmad, H. A. et al. Signaling Pathways in Drug Development.\u00a0IntechOpen. https:\/\/doi.org\/10.5772\/INTECHOPEN.114041. (2024).","journal-title":"IntechOpen"},{"key":"3813_CR63","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.1038\/s41467-022-33291-z","volume":"13","author":"S Chawla","year":"2022","unstructured":"Chawla, S. et al. Gene expression based inference of cancer drug sensitivity. Nat. Commun. 13, 5680 (2022).","journal-title":"Nat. Commun."},{"key":"3813_CR64","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fimmu.2018.00221","volume":"9","author":"D Bahia","year":"2018","unstructured":"Bahia, D., Satoskar, A. R. & Dussurget, O. Editorial: Cell signaling in host\u2013Pathogen interactions: the host point of view. Front. Immunol. 9, 221 (2018).","journal-title":"Front. Immunol."},{"key":"3813_CR65","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1016\/j.bpj.2021.06.006","volume":"120","author":"M Wilamowski","year":"2021","unstructured":"Wilamowski, M. et al. Transient and stabilized complexes of Nsp7, Nsp8, and Nsp12 in SARS-CoV-2 replication. Biophys. J. 120, 3152\u20133165 (2021).","journal-title":"Biophys. J."},{"key":"3813_CR66","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"DE Gordon","year":"2020","unstructured":"Gordon, D. E. et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature\u00a0583, 459\u2013468 (2020).","journal-title":"Nature"},{"key":"3813_CR67","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/978-1-0716-3056-3_8","volume":"2645","author":"A Chary","year":"2023","unstructured":"Chary, A. Culturing human lung adenocarcinoma cells in a Serum-Free environment. Methods Mol. Biol. 2645, 165\u2013172 (2023).","journal-title":"Methods Mol. Biol."},{"key":"3813_CR68","doi-asserted-by":"publisher","first-page":"105423","DOI":"10.1016\/j.tiv.2022.105423","volume":"83","author":"A Chary","year":"2022","unstructured":"Chary, A. et al. Maximizing the relevance and reproducibility of A549 cell culture using FBS-free media. Toxicol. Vitr. 83, 105423 (2022).","journal-title":"Toxicol. Vitr"},{"key":"3813_CR69","doi-asserted-by":"publisher","first-page":"e3001091","DOI":"10.1371\/journal.pbio.3001091","volume":"19","author":"SJ Rihn","year":"2021","unstructured":"Rihn, S. J. et al. A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. PLOS Biol. 19, e3001091 (2021).","journal-title":"PLOS Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03813-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03813-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03813-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:02:00Z","timestamp":1748304120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03813-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3813"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03813-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18443"}}